Home › Companies › CULLINAN THERAPEUTICS INC. › 2024-2025

CULLINAN THERAPEUTICS INC. 2024-2025 Proxy Voting Records

Compiled from SEC Form N-PX filings and CULLINAN THERAPEUTICS INC.’s Form 8-K, filed 2025-06-12 (Item 5.07 on EDGAR). Page generated 02 October 2026.

6Reported items
155Asset managers
1,191Fund votes
2025-06-12Meeting date

Proxy season: 2024-2025 2025-2026

Explore CULLINAN THERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by CULLINAN THERAPEUTICS INC.

These tallies are CULLINAN THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2025-06-12 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

CULLINAN THERAPEUTICS INC. — official shareholder meeting results, meeting held 2025-06-12
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Anthony Rosenberg	47,044,236	--	--	1,926,370	3,138,175	Majority: yes
Elect Director: David P. Ryan, M.D.	47,241,434	--	--	1,729,172	3,138,175	Majority: yes
Elect Director: Mary Thistle	48,835,369	--	--	135,237	3,138,175	Majority: yes
Proposal Three — Advisory Vote on Executive Compensation The Company's stockholders approved the advisory vote on the compensation of the Company's named executive officers by the following votes:	46,956,042	1,999,889	14,675	--	3,138,175	Majority: yes

Source: CULLINAN THERAPEUTICS INC., Form 8-K, filed with the SEC on 2025-06-12 — read the filing on EDGAR.

How asset managers voted at the CULLINAN THERAPEUTICS INC. 2024-2025 meeting

Each item below shows how the 155 asset managers that disclosed a CULLINAN THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of CULLINAN THERAPEUTICS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. PROPOSAL TO VOTE, ON AN ADVISORY BASIS, TO APPROVE OUR NAMED EXECUTIVE OFFICER COMPENSATION.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 6 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%

FOR: 46,956,042AGAINST: 1,999,889

CULLINAN THERAPEUTICS INC.’s own tally for this item (“Proposal Three — Advisory Vote on Executive Compensation The Company's stockholders approved the advisory vote on the compensation of the Company's named executive officers by the following votes:”): 46,956,042 for, 1,999,889 against, per its Form 8-K filed 2025-06-12 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 58,698,919 outstanding shares: 80% for, 3% against (83% of the company cast a for/against vote).

The 155 asset managers below cast 94% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.

FOR 92%

FOR: 91.6%AGAINST: 5.8%ABSTAIN: 2.7%

Largest asset managers voting on “PROPOSAL TO VOTE, ON AN ADVISORY BASIS, TO APPROVE OUR NAMED EXECUTIVE OFFICER COMPENSATION.” at CULLINAN THERAPEUTICS INC., 2024-2025
Asset manager	For	Against	Abstain	Vote
MPM BioImpact LLC	7,648,268	0	0	For
BVF INC/IL	5,750,683	0	0	For
DEERFIELD MANAGEMENT COMPANY, L.P.	3,650,893	0	0	For
Lynx1 Capital Management LP	3,339,816	0	0	For
Vanguard	3,070,521	0	0	For
BlackRock	2,636,789	10,124	0	For
AllianceBernstein	0	2,550,291	0	Against
Blue Owl Capital Holdings LP	2,435,948	0	0	For
FRANKLIN ADVISERS INC	2,180,871	0	0	For
ORBIMED ADVISORS LLC	1,923,855	0	0	For
RTW INVESTMENTS, LP	1,705,960	0	0	For
State Street	1,490,074	351	0	For
Kynam Capital Management, LP	0	0	1,417,426	Abstain
VR Adviser, LLC	1,379,965	0	0	For
Citadel	1,301,496	0	0	For
FRANKLIN STRATEGIC SERIES	1,268,994	0	0	For
GEODE CAPITAL MANAGEMENT, LLC	1,246,282	0	0	For
Fidelity	1,126,854	0	0	For
Siren, L.L.C.	1,044,094	0	0	For
Charles Schwab	869,022	0	0	For
BRAIDWELL LP	834,651	0	0	For
Rock Springs Capital Management LP	644,633	0	0	For
Foresite Capital Management VI LLC	634,558	0	0	For
MARSHALL WACE, LLP	575,712	0	0	For
Dimensional	372,425	0	0	For

Showing the 25 largest of 155 asset managers. See all 155 in the interactive database.

2. PROPOSAL TO VOTE, ON AN ADVISORY BASIS, ON THE FREQUENCY OF FUTURE ADVISORY VOTES ON OUR NAMED EXECUTIVE OFFICER COMPENSATION.

SECTION 14A SAY-ON-PAY VOTES

Combines 4 wordings of this item as funds reported it.

99.9% fund support · no official result

1 YEAR 43%ONE YEAR 38%11%

The 151 asset managers below cast 99.9% of the shares they voted on this item FOR (2,638,679 for, 20 against).

FOR: 2,638,679 (4.9%)AGAINST: 20 (0.0%)ABSTAIN: 1,431,274 (2.7%)1 YEAR: 23,112,384 (42.9%)ONE YEAR: 20,541,276 (38.1%)1-YR: 5,750,683 (10.7%)THREE YEARS: 385,154 (0.7%)3 YEARS: 10,589 (0.0%)1-YEAR: 974 (0.0%)

Largest asset managers voting on “PROPOSAL TO VOTE, ON AN ADVISORY BASIS, ON THE FREQUENCY OF FUTURE ADVISORY VOTES ON OUR NAMED EXECUTIVE OFFIC” at CULLINAN THERAPEUTICS INC., 2024-2025
Asset manager	For	Abstain	Vote
MPM BioImpact LLC	0	0	1 Year
BVF INC/IL	0	0	1-Yr
DEERFIELD MANAGEMENT COMPANY, L.P.	0	0	1 Year
Lynx1 Capital Management LP	0	0	1 Year
Vanguard	0	0	One Year
BlackRock	0	0	1 Year
AllianceBernstein	0	0	One Year
Blue Owl Capital Holdings LP	2,435,948	0	For
FRANKLIN ADVISERS INC	0	0	One Year
ORBIMED ADVISORS LLC	0	0	1 Year
RTW INVESTMENTS, LP	0	0	One Year
State Street	0	0	One Year
Kynam Capital Management, LP	0	1,417,426	Abstain
VR Adviser, LLC	0	0	One Year
Citadel	0	0	One Year
FRANKLIN STRATEGIC SERIES	0	0	One Year
GEODE CAPITAL MANAGEMENT, LLC	0	0	One Year
Fidelity	0	0	One Year
Siren, L.L.C.	0	0	1 Year
Charles Schwab	0	0	1 Year
BRAIDWELL LP	0	0	One Year
Rock Springs Capital Management LP	0	0	One Year
Foresite Capital Management VI LLC	0	0	1 Year
MARSHALL WACE, LLP	0	0	1 Year
Dimensional	0	0	Three Years

Showing the 25 largest of 151 asset managers. See all 151 in the interactive database.

3. Election of the following individuals nominated to serve as Class II directors, for a three-year term ending at the annual meeting of stockholders to be held in 2028: Anthony Rosenberg

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%

FOR: 47,044,236WITHHELD: 1,926,370

CULLINAN THERAPEUTICS INC.’s own tally for this item (“Elect Director: Anthony Rosenberg”): 47,044,236 for, 1,926,370 withheld, per its Form 8-K filed 2025-06-12 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 58,698,919 outstanding shares: 80% for, 3% withheld (83% of the company cast a for/withheld vote).

The 47 asset managers below cast 100% of the shares they voted on this item FOR (8,302,141 for, 0 against).

FOR 87%13%

FOR: 8,302,141 (87.5%)ABSTAIN: 1,189,443 (12.5%)

Largest asset managers voting on “Election of the following individuals nominated to serve as Class II directors, for a three-year term ending a” at CULLINAN THERAPEUTICS INC., 2024-2025
Asset manager	For	Abstain	Vote
Vanguard	2,954,348	0	For
FRANKLIN STRATEGIC SERIES	1,268,994	0	For
BlackRock	1,224,102	0	For
Fidelity	1,123,715	0	For
AllianceBernstein	0	950,416	Abstain
Charles Schwab	427,114	0	For
State Street	260,622	0	For
Dimensional	201,261	0	For
TIAA	187,390	0	For
Principal	0	175,879	Abstain
Equitable	91,445	44,060	For
American Century	115,514	0	For
Lincoln Financial	73,344	0	For
Northern Trust	42,862	0	For
Tema ETF Trust	39,605	0	For
Brighthouse	19,002	13,848	For
Global X	30,183	0	For
AIG/SunAmerica	26,697	0	For
Direxion Shares ETF Trust	25,103	0	For
ProShares	22,904	0	For
John Hancock	20,934	0	For
Pacific Life	17,335	0	For
Voya	14,397	0	For
ETF Series Solutions	14,107	0	For
T. Rowe Price	13,084	0	For

Showing the 25 largest of 47 asset managers. See all 47 in the interactive database.

4. Election of the following individuals nominated to serve as Class II directors, for a three-year term ending at the annual meeting of stockholders to be held in 2028: David P. Ryan, M.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%

FOR: 47,241,434WITHHELD: 1,729,172

CULLINAN THERAPEUTICS INC.’s own tally for this item (“Elect Director: David P. Ryan, M.D.”): 47,241,434 for, 1,729,172 withheld, per its Form 8-K filed 2025-06-12 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 58,698,919 outstanding shares: 80% for, 3% withheld (83% of the company cast a for/withheld vote).

The 47 asset managers below cast 100% of the shares they voted on this item FOR (8,307,381 for, 0 against).

FOR 88%12%

FOR: 8,307,381 (87.5%)ABSTAIN: 1,184,203 (12.5%)

Largest asset managers voting on “Election of the following individuals nominated to serve as Class II directors, for a three-year term ending a” at CULLINAN THERAPEUTICS INC., 2024-2025
Asset manager	For	Abstain	Vote
Vanguard	2,954,348	0	For
FRANKLIN STRATEGIC SERIES	1,268,994	0	For
BlackRock	1,224,102	0	For
Fidelity	1,123,715	0	For
AllianceBernstein	0	950,416	Abstain
Charles Schwab	427,114	0	For
State Street	260,622	0	For
Dimensional	201,261	0	For
TIAA	187,390	0	For
Principal	0	175,879	Abstain
Equitable	91,445	44,060	For
American Century	115,514	0	For
Lincoln Financial	73,344	0	For
Northern Trust	42,862	0	For
Tema ETF Trust	39,605	0	For
Brighthouse	19,002	13,848	For
Global X	30,183	0	For
AIG/SunAmerica	26,697	0	For
Direxion Shares ETF Trust	25,103	0	For
ProShares	22,904	0	For
John Hancock	20,934	0	For
Pacific Life	17,335	0	For
Voya	14,397	0	For
ETF Series Solutions	14,107	0	For
T. Rowe Price	13,084	0	For

Showing the 25 largest of 47 asset managers. See all 47 in the interactive database.

5. Election of the following individuals nominated to serve as Class II directors, for a three-year term ending at the annual meeting of stockholders to be held in 2028: Mary Thistle

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

99.7% Majority: yes · of votes cast

FOR 99.7%

FOR: 48,835,369WITHHELD: 135,237

CULLINAN THERAPEUTICS INC.’s own tally for this item (“Elect Director: Mary Thistle”): 48,835,369 for, 135,237 withheld, per its Form 8-K filed 2025-06-12 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 58,698,919 outstanding shares: 83% for, 0.3% withheld (83% of the company cast a for/withheld vote).

The 47 asset managers below cast 100% of the shares they voted on this item FOR (9,477,736 for, 0 against).

FOR 99.8%

FOR: 9,477,736 (99.9%)ABSTAIN: 13,848 (0.1%)

Largest asset managers voting on “Election of the following individuals nominated to serve as Class II directors, for a three-year term ending a” at CULLINAN THERAPEUTICS INC., 2024-2025
Asset manager	For	Abstain	Vote
Vanguard	2,954,348	0	For
FRANKLIN STRATEGIC SERIES	1,268,994	0	For
BlackRock	1,224,102	0	For
Fidelity	1,123,715	0	For
AllianceBernstein	950,416	0	For
Charles Schwab	427,114	0	For
State Street	260,622	0	For
Dimensional	201,261	0	For
TIAA	187,390	0	For
Principal	175,879	0	For
Equitable	135,505	0	For
American Century	115,514	0	For
Lincoln Financial	73,344	0	For
Northern Trust	42,862	0	For
Tema ETF Trust	39,605	0	For
Brighthouse	19,002	13,848	For
Global X	30,183	0	For
AIG/SunAmerica	26,697	0	For
Direxion Shares ETF Trust	25,103	0	For
ProShares	22,904	0	For
John Hancock	20,934	0	For
Pacific Life	17,335	0	For
Voya	14,397	0	For
ETF Series Solutions	14,107	0	For
T. Rowe Price	13,084	0	For

Showing the 25 largest of 47 asset managers. See all 47 in the interactive database.

6. Proposal to ratify the appointment of KPMG LLP as Cullinan Therapeutics' independent registered public accounting firm for the fiscal year ending December 31, 2025.

AUDIT-RELATED

99.9% fund support · no official result

FOR 99.8%

The 47 asset managers below cast 99.9% of the shares they voted on this item FOR (9,477,626 for, 110 against).

FOR: 9,477,626 (99.9%)AGAINST: 110 (0.0%)ABSTAIN: 13,848 (0.1%)

Largest asset managers voting on “Proposal to ratify the appointment of KPMG LLP as Cullinan Therapeutics' independent registered public account” at CULLINAN THERAPEUTICS INC., 2024-2025
Asset manager	For	Abstain	Vote
Vanguard	2,954,348	0	For
FRANKLIN STRATEGIC SERIES	1,268,994	0	For
BlackRock	1,224,102	0	For
Fidelity	1,123,715	0	For
AllianceBernstein	950,416	0	For
Charles Schwab	427,114	0	For
State Street	260,622	0	For
Dimensional	201,261	0	For
TIAA	187,390	0	For
Principal	175,879	0	For
Equitable	135,505	0	For
American Century	115,514	0	For
Lincoln Financial	73,344	0	For
Northern Trust	42,862	0	For
Tema ETF Trust	39,605	0	For
Brighthouse	19,002	13,848	For
Global X	30,183	0	For
AIG/SunAmerica	26,697	0	For
Direxion Shares ETF Trust	25,103	0	For
ProShares	22,904	0	For
John Hancock	20,934	0	For
Pacific Life	17,335	0	For
Voya	14,397	0	For
ETF Series Solutions	14,107	0	For
T. Rowe Price	13,084	0	For

Showing the 25 largest of 47 asset managers. See all 47 in the interactive database.

Largest CULLINAN THERAPEUTICS INC. shareholders voting in 2024-2025

Ranked by the number of CULLINAN THERAPEUTICS INC. shares each manager voted on the most widely held ballot item of the 2024-2025 meeting, shown as a share of the 58,698,919 shares outstanding at the time of that meeting.

Top CULLINAN THERAPEUTICS INC. shareholders by shares voted, 2024-2025
#	Asset manager	% of shares outstanding
1	MPM BioImpact LLC	13.03%
2	BVF INC/IL	9.80%
3	DEERFIELD MANAGEMENT COMPANY, L.P.	6.22%
4	Lynx1 Capital Management LP	5.69%
5	Vanguard	5.23%
6	BlackRock	4.51%
7	AllianceBernstein	4.34%
8	Blue Owl Capital Holdings LP	4.15%
9	FRANKLIN ADVISERS INC	3.72%
10	ORBIMED ADVISORS LLC	3.28%

Reported CULLINAN THERAPEUTICS INC. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

CULLINAN THERAPEUTICS INC. beneficial owners on record for the 2024-2025 proxy season
Holder	% outstanding	Disclosure
BVF PARTNERS L P/IL	10.50%	13G
LYNX1 CAPITAL MANAGEMENT LP	9.82%	13G
BlackRock	7.19%	13F
Vanguard Group	5.18%	13F
Deerfield Mgmt, L.P.	4.99%	13G
Citadel Advisors	4.72%	13F
Franklin Templeton	3.78%	13F
Kenneth Griffin	3.39%	13G
State Street	2.99%	13F
Dimensional Fund Advisors	2.22%	13F

Percentages above are of 58,698,919 shares outstanding, as reported by CULLINAN THERAPEUTICS INC. on its Form 10-Q dated 2025-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from CULLINAN THERAPEUTICS INC.’s 10-Q dated 2025-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At CULLINAN THERAPEUTICS INC.'s shareholder meeting held 2025-06-12, in the 2024-2025 proxy season, 155 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,191 separate fund positions. Their filings are grouped here into 6 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — PROPOSAL TO VOTE, ON AN ADVISORY BASIS, TO APPROVE OUR NAMED EXECUTIVE OFFICER COMPENSATION. — FOR was 96% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: CULLINAN THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2025-06-12.

CULLINAN THERAPEUTICS INC. proxy season coverage: 2024-2025 (this page) · 2025-2026.